The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Growth Fund - Series I
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neomile Growth Fund - Series I, along with PAC Neomile Corporate Advisory Limited, sold 14,75,992 equity shares (2.78%) of Anlon Healthcare Ltd in the open market between November 3 and November 4, 2025. The seller is not part of the promoter/promoter group. Before the sale, the fund held 55,28,667 shares (10.40% of total equity), which has now come down to 40,52,675 shares (7.62%). The disclosure was filed under SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, triggered because the fund crossed below the 10% substantial shareholder threshold. Anlon Healthcare's total equity share capital remains unchanged at 5,31,51,500 shares.
A non-promoter institutional investor has trimmed its stake meaningfully and dropped below the 10% significant-shareholder mark. For retail investors, this signals a large fund reducing conviction in the stock, which may weigh on short-term sentiment, though no promoter-level changes are involved.